Watts Gerald F, Chan Dick C, Barrett P Hugh R
Department of Medicine, University of Western Australia, Western Australian Institute for Medical Research, Royal Perth Hospital, Australia.
Metabolism. 2002 Sep;51(9):1206-10. doi: 10.1053/meta.2002.34718.
We examined the association between the kinetics of very-low-density lipoprotein (VLDL) apolipoprotein B-100 (apoB) and intraperitoneal, retroperitoneal, subcutaneous abdominal, and total adipose tissue masses (IPATM, RPATM, SAATM, TATM, respectively) in 14 healthy, non-obese men (body mass index [BMI] < 30 kg/m(2)). Hepatic secretion of VLDL-apoB was measured using an intravenous infusion of 1-[(13)C]-leucine. Isotopic enrichment of VLDL-apoB was measured using gas chromatography-mass-spectrometry and a multicompartmental model (Simulation, Analysis, and Modeling Software [SAAM II]) used to estimate the fractional catabolic rate (FCR) of VLDL-apoB. IPATM, RPATM, and SAATM (kg) were quantified between T11 and S1 using magnetic resonance imaging (MRI); TATM (kg) was determined using bioelectrical impedance. Insulin resistance was estimated by homeostasis model assessment (HOMA) score. In stepwise regression analysis, IPATM was the best predictor of the hepatic secretion of VLDL-apoB (r =.58, P <.05) and TATM the best predictor of the FCR of VLDL-apoB (r = -.56, P <.05). After adjusting for TATM, IPATM explained 59% of the variance in VLDL apoB secretion (P =.03). None of the fat compartments were significantly associated with VLDL-apoB kinetics after adjusting for HOMA score. The findings suggest that in non-obese men the quantity of both intraperitoneal and total fat are significant predictors for the kinetics of VLDL-apoB, which in turn, determines plasma triglyceride concentrations; these associations may, in part, be mediated by variations in insulin resistance, particularly among individual who are not ostensibly obese. Our preliminary results need confirmation in a larger study.
我们研究了14名健康、非肥胖男性（体重指数[BMI]<30kg/m²）极低密度脂蛋白（VLDL）载脂蛋白B-100（apoB）的动力学与腹膜内、腹膜后、腹部皮下及总脂肪组织质量（分别为IPATM、RPATM、SAATM、TATM）之间的关联。使用静脉输注1-[(13)C]-亮氨酸来测量VLDL-apoB的肝脏分泌。使用气相色谱-质谱法测量VLDL-apoB的同位素富集，并使用多室模型（模拟、分析和建模软件[SAAM II]）来估计VLDL-apoB的分解代谢率（FCR）。使用磁共振成像（MRI）在T11和S1之间对IPATM、RPATM和SAATM（kg）进行定量；使用生物电阻抗法测定TATM（kg）。通过稳态模型评估（HOMA）评分估计胰岛素抵抗。在逐步回归分析中，IPATM是VLDL-apoB肝脏分泌的最佳预测指标（r = 0.58，P < 0.05），TATM是VLDL-apoB的FCR的最佳预测指标（r = -0.56，P < 0.05）。在调整TATM后，IPATM解释了VLDL apoB分泌中59%的变异（P = 0.03）。在调整HOMA评分后，没有一个脂肪区与VLDL-apoB动力学显著相关。研究结果表明，在非肥胖男性中，腹膜内脂肪和总脂肪的量都是VLDL-apoB动力学的重要预测指标，而VLDL-apoB动力学又决定了血浆甘油三酯浓度；这些关联可能部分由胰岛素抵抗的变化介导，尤其是在表面上不肥胖的个体中。我们的初步结果需要在更大规模的研究中得到证实。
